You are here

Gilead remdesivir results mixed in moderate Covid-19 patients

doc7atugvmhon91j32vzicq_doc7aoca0qx80w1k27k32u7.jpg
Gilead Sciences said on Monday its antiviral drug remdesivir had mixed results in a late stage study of people with moderate Covid-19, as patients given a five-day course of the treatment showed statistically significant improvement, while those given it for 10-days did not.

[CALIFORNIA] Gilead Sciences said on Monday its antiviral drug remdesivir had mixed results in a late stage study of people with moderate Covid-19, as patients given a five-day course of the treatment showed statistically significant improvement, while those given it for 10-days did not.

...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes